Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ccedaf5d2bb07be41556fde75cd82c92 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-36122 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2035-122 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5156 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-36162 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-36142 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7088 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-162 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0687 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5008 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7088 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-02 |
filingDate |
2020-07-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c41c13cb566292209f04d5f734c9e838 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d11408de5b4b97140a02d0af72cabc78 |
publicationDate |
2021-01-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
WO-2021016293-A1 |
titleOfInvention |
Immunomodulatory compositions and methods of using |
abstract |
Immunomodulatory compositions that include at least one alphavirus capsid protein and methods of using such immunomodulatory compositions. In one aspect, methods of immunomodulating IL-1/TLR signaling in a cell are provided. Such methods typically include contacting the cell with an alphavirus capsid protein or a portion thereof, thereby immunomodulating IL-1/TLR signaling in the cell. |
priorityDate |
2019-07-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |